证券代码：603439 证券简称：贵州三力 公告编号：2025-042 贵州三力制药股份有限公司关于部分董事兼 高级管理人员提前终止减持计划暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 部分董事兼高级管理人员持股的基本情况 本次减持前，贵州三力制药股份有限公司（以下简称"公司"）董事兼副总 经理王毅先生持有公司股份 1,335,000 股，占公司总股本的 0.3258% 减持计划的实施结果情况 公司于 2025 年 6 月 12 日披露了《贵州三力制药股份有限公司持股 5%以上 股东及董事、高管减持股份计划公告》（公告编号：2025-033），王毅先生计划通 过集中竞价交易方式减持公司股份不超过 333,750 股（不超过公司总股本的 0.0814%），减持期间为 2025 年 7 月 3 日～2025 年 10 月 2 日。 | 股东名称 | 王毅 | | | | --- | --- | --- | --- | | | 控股股东、实控人及一致行动人 | □是 | √否 | | 股东 ...

证券代码：603439 证券简称：贵州三力 公告编号：2025-041 贵州三力制药股份有限公司关于部分高级管理人员 近日，公司收到余渊先生和罗战彪先生分别出具的《关于减持计划实施完毕 的告知函》。截至 2025 年 7 月 9 日，余渊先生通过集中竞价交易方式减持公司股 份 45,000 股，占公司总股本 0.0110%，余渊先生本次减持计划已实施完毕；罗战 彪先生通过集中竞价交易方式减持公司股份 60,000 股，占公司总股本 0.0146%， 罗战彪先生本次减持计划已实施完毕。 一、减持主体减持前基本情况 股东名称 余渊 股东身份 控股股东、实控人及一致行动人 □是 √否 直接持股 5%以上股东 □是 √否 董事、监事和高级管理人员 √是 □否 其他：不适用 持股数量 325,000股 持股比例 0.0793% 当前持股股份来源 其他方式取得：325,000股 股东名称 罗战彪 控股股东、实控人及一致行动人 □是 √否 直接持股 5%以上股东 □是 √否 股东身份 董事、监事和高级管理人员 √是 □否 其他：不适用 持股数量 370,000股 持股比例 0.0903% 当前持股股份来源 其他方式取得：3 ...

证券代码：603439 证券简称：贵州三力 公告编号：2025-041 本次减持前，贵州三力制药股份有限公司（以下简称"公司"）副总经理余 渊先生持有公司股份 325,000 股，占公司总股本的 0.0793%；公司副总经理罗战 彪先生持有公司股份 370,000 股，占公司总股本的 0.0903% 减持计划的实施结果情况 公司于 2025 年 6 月 12 日披露了《贵州三力制药股份有限公司持股 5%以上 股东及董事、高管减持股份计划公告》（公告编号：2025-033），余渊先生计划通 过集中竞价交易方式减持公司股份不超过 45,000 股（不超过公司总股本的 0.0110%），减持期间为 2025 年 7 月 3 日～2025 年 10 月 2 日；罗战彪先生计划 通过集中竞价交易方式减持公司股份不超过 60,000 股（不超过公司总股本的 0.0146%），减持期间为 2025 年 7 月 3 日～2025 年 10 月 2 日。 近日，公司收到余渊先生和罗战彪先生分别出具的《关于减持计划实施完毕 的告知函》。截至 2025 年 7 月 9 日，余渊先生通过集中竞价交易方式减持公司股 份 45,000 ...

Summary of Key Points Core Viewpoint - The announcement details the completion of a share reduction plan by Zhang Qianfan, the Vice Chairman and General Manager of Guizhou Sanli Pharmaceutical Co., Ltd, who reduced his holdings in the company through a concentrated bidding process. Group 1: Shareholding Information - Before the reduction plan, Zhang Qianfan held 714,600 shares, representing 0.1744% of the company's total share capital [1] - The reduction plan was initially disclosed on June 12, 2025, with a maximum planned reduction of 178,650 shares, which is 0.0436% of the total share capital [1][2] Group 2: Reduction Implementation Results - As of July 7, 2025, Zhang Qianfan successfully reduced his holdings by 178,650 shares through concentrated bidding, achieving the planned reduction [2][3] - The shares were sold within a price range of 11.85 to 11.95 yuan per share, totaling approximately 2,122,303.23 yuan [2] - After the reduction, Zhang Qianfan's remaining shares amount to 535,950, which is 0.1308% of the total share capital [2]

证券代码：603439 证券简称：贵州三力 公告编号：2025-040 贵州三力制药股份有限公司关于部分董事兼 高级管理人员减持计划实施完毕暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、减持主体减持前基本情况 部分董事兼高级管理人员持股的基本情况 本次减持计划实施前，贵州三力制药股份有限公司（以下简称"公司"）副 董事长、总经理、董事会秘书张千帆先生持有公司股份 714,600 股，占公司总股 本的 0.1744%。 减持计划的实施结果情况 公司于 2025 年 6 月 12 日披露了《贵州三力制药股份有限公司持股 5%以上 股东及董事、高管减持股份计划公告》（公告编号：2025-033），张千帆先生计划 通过集中竞价交易方式减持其所持有的公司股份不超过 178,650 股（不超过公司 总股本的 0.0436%），减持期间为 2025 年 7 月 3 日至 2025 年 10 月 2 日。 近日，公司收到张千帆先生出具的《关于减持计划实施完毕的告知函》。截 至 2025 年 7 ...

贵州三力制药股份有限公司（以下简称"公司"）董事会近日收到公司副总 经理张红玉女士递交的书面辞职报告。张红玉女士因到龄退休，申请辞去公司副 总经理职务，辞职后不再担任公司及子公司任何职务。 姓名 离任职务 离任时间 原定任期 到期日 离任原 因 是否继续在上 市公司及其控 股子公司任职 是否存在未 履行完毕的 公开承诺 张红玉 副总经理 2025 年 7 月 7 日 2027 年 5 月 17 日 退休 否 否 一、高级管理人员提前离任的基本情况 证券代码：603439 证券简称：贵州三力 公告编号：2025-039 贵州三力制药股份有限公司 关于高级管理人员离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 张红玉女士任职期间恪尽职守、勤勉尽责。公司及董事会对张红玉女士在任 职期间为公司发展所作出的重要贡献表示衷心感谢！ 特此公告。 贵州三力制药股份有限公司董事会 2025 年 7 月 8 日 二、离任对公司的影响 根据《公司法》《公司章程》等法律法规的相关规定，上述辞职报告自送达 董事会之日起生效，张红玉女士所负 ...

贵州三力制药股份有限公司（以下简称"公司"）于2024年9月12日召开了第四届董 事会第四次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议 案》。同意公司使用自有资金通过集中竞价交易方式进行股份回购，回购股份将全部用 于后期实施员工持股计划或股权激励计划，回购资金总额不低于人民币8,000.00万 元（含），不超过人民币12,000.00万元（含），回购价格不超过人民币17.85元/股（含） ，回购期限自公司董事会审议通过回购股份方案之日起12个月内。具体内容详见公司 在上海证券交易所网站（www.sse.com.cn）披露的《贵州三力制药股份有限公司关 于以集中竞价交易方式回购公司股份方案的公告暨回购报告书》（公告编号： 2024-054）。 证券代码：603439 证券简称：贵州三力 公告编号：2025-038 贵州三力制药股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/9/13 | | | | | | --- | -- ...

Core Viewpoint - The company has announced a profit distribution plan for the fiscal year 2024, which was approved at the annual shareholders' meeting on May 17, 2025 [1]. Distribution Plan - The profit distribution will be based on a total share capital of 409,802,216 shares, with 4,982,200 shares excluded from the distribution due to being held in a repurchase account, resulting in 404,820,016 shares eligible for distribution [2]. - Each eligible share will receive a cash dividend of 0.34 yuan (including tax), totaling 137,638,805.44 yuan (including tax) to be distributed [2]. Calculation of Ex-Dividend Price - The ex-dividend reference price will be calculated using the formula: Ex-dividend reference price = [(Previous closing price - Cash dividend) + (Subscription price × Change in circulating shares ratio)] / (1 + Change in circulating shares ratio) [3]. - The cash dividend per share, after dilution adjustment, is approximately 0.3359 yuan per share [3]. Dividend Distribution Method - Cash dividends for unrestricted circulating shareholders will be distributed through the China Securities Depository and Clearing Corporation Limited, Shanghai Branch [6]. - Shareholders who have not completed designated trading will have their dividends held by the clearing company until they complete the necessary transactions [6]. Taxation Details - For individual shareholders holding unrestricted circulating shares, dividends are subject to different tax treatments based on the holding period, with a maximum tax rate of 20% for shares held for less than one month [8]. - For shares held for more than one year, dividends are exempt from personal income tax [8]. - For foreign institutional investors, a 10% withholding tax will apply, resulting in a net cash dividend of 0.306 yuan per share [9]. Contact Information - For inquiries regarding the profit distribution, shareholders can contact the Securities Division at 0851-38113395 [11].

Core Viewpoint - Guizhou Sanli Pharmaceutical Co., Ltd. is implementing a differentiated dividend distribution plan due to the repurchase of shares and the cancellation of certain restricted stocks, ensuring compliance with relevant laws and regulations [2][7]. Group 1: Reasons for Differentiated Dividend - The company plans to repurchase and cancel 60,000 restricted stocks from one employee who no longer qualifies for the incentive program due to resignation [3]. - Additionally, 732,000 restricted stocks from seven employees will be repurchased and canceled as the company's performance did not meet the conditions for the third release period of the 2021 incentive plan [3]. Group 2: Dividend Distribution Plan - The total share capital of the company is 409,802,216 shares, and the company will distribute a cash dividend of 3.40 yuan (including tax) for every 10 shares to eligible shareholders, adjusting the total distribution amount accordingly due to the repurchased shares [5][6]. - The total cash dividend to be distributed amounts to 137,638,805.44 yuan (including tax) [5]. Group 3: Calculation Basis for Differentiated Dividend - As of May 29, 2024, the closing price of the company's shares was 12.02 yuan per share, with a total of 4,982,200 shares in the repurchase account [6]. - The reference price for ex-dividend is calculated to be approximately 11.68 yuan per share, with a minimal impact of 0.0351% on the reference price due to the differentiated dividend distribution [6][7]. Group 4: Legal Compliance and Conclusion - The legal opinion confirms that the differentiated dividend distribution complies with the Company Law, Securities Law, and relevant regulations, and does not harm the interests of the company or its shareholders [7].

Core Points - Guizhou Sanli Pharmaceutical Co., Ltd. has announced a cash dividend distribution plan, with a cash dividend of RMB 0.34 per share, totaling RMB 137,638,805.44 (including tax) for the participating shareholders [1][2][4] - The total number of shares participating in the distribution is 404,820,016 shares after excluding 4,982,200 shares that do not participate due to being held in a repurchase account [2][3] - The record date for the dividend distribution is June 25, 2025, with the ex-dividend date also set for June 26, 2025 [3][4] Dividend Distribution Details - The cash dividend will be distributed to shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the record date [1][3] - The company will not issue bonus shares or increase capital through the dividend distribution, meaning the number of circulating shares will remain unchanged [2][3] - The reference price for the ex-dividend will be calculated based on the formula: (previous closing price - cash dividend) [2][3] Tax Implications - For individual shareholders holding shares for more than one year, the cash dividend is exempt from personal income tax, resulting in an actual distribution of RMB 0.34 per share [6] - For shares held for less than one year, the tax will be calculated upon transfer, with a 20% tax rate applicable for holdings of one month or less [6][7] - Qualified Foreign Institutional Investors (QFII) will have a 10% withholding tax applied, resulting in a net cash dividend of RMB 0.306 per share [7][8]